ANIX · Anixa Biosciences Inc
$3.71
-0.05 (-1.20%)
At close · Jul 24
Market Cap
$125.89M
Shares
34.02M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.75
Open$3.55
Day$3.47–3.83
52W$2.32–5.46
Avg vol 30d294K
Short int862K · 2.5% float · 3.1d
Short vol69%
DataJan 2020–Jul 2026
Filing10-Q · Jun 10
Up next
FQ3-26 quarter ends
~Jul 31, 2026
Est
filed Jun 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+31%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
46%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+37%
trailing
6-month return
+21%
trailing
YTD return
+20%
this year
Relative strength
+15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
7 of 62 funds reported for Jun 30 · net +347 sh shares
Insider flow
Accumulating
Net +$143.3K over 90 days · 0% sells
Short interest
Falling
2.53% of float · ▼ -2.7% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
62 holders — mid 3-yr range
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
0%
Y/Y
EPS growth
+13%
Y/Y
Free cash flow
$-7.2M
Balance sheet
$873.8K
net cash
Quant / Vol
risk profile
Volatility
73%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+31%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
46%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Accumulating
7 of 62 funds reported for Jun 30 · net +347 sh shares
Insider flow
Accumulating
Net +$143.3K over 90 days · 0% sells
Short interest
Falling
2.53% of float · ▼ -2.7% MoM · 3.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
62 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $4 · 46%
52-wk high $5
vs 200-day avg +14%
vs 50-day avg +31%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ANIX
this stock
Anixa Biosciences Inc
|
$125.89M | +20.2% | +0.0% | — | 2.5% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ANIX | +13.0% | +36.9% | +21.0% | +33.9% | +20.2% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | +14.6% | +36.2% | +14.6% | +35.1% | +11.9% |